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ABSTRACT
Osteosarcoma (OSA) is the most common primary bone tumor in humans. However, the cell of origin of OSA is not clearly deﬁned although
there is evidence that osteoblasts may serve as OSA progenitors. The role of osteocytes, terminally differentiated osteoblasts, as OSA
progenitors has yet to be described. Analysis of patient cDNA from publicly available microarray data revealed that patients with OSA have
increased expression of dentin matrix phosphoprotein 1 (DMP1), a marker of osteocytes. Analysis of multiple murine, human, and canine OSA
cell lines revealed DMP1 expression. To test the tumorigenic potential of osteocytes, MLO-Y4, a SV-40 immortalizedmurine osteocyte cell line,
was injected into subcutaneous and orthotopic (intratibial) sites of mice. Tumor growth occurred in both locations. Orthotopic MLO-Y4 tumors
produced mixed osteoblastic/osteolytic radiographic lesions; a hallmark of OSA. Together, these data demonstrate for the ﬁrst time that
osteocytes can serve as OSA progenitors. J. Cell. Biochem. 115: 1420–1429, 2014. © 2014 Wiley Periodicals, Inc.
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Osteosarcoma (OSA), which mainly impacts adolescents, is themost common primary bone tumor of humans [Bielack
et al., 2008]. OSA only has a 60% 5-year survival rate due to a high
incidence of lung metastasis at the time of diagnosis [Bielack
et al., 2008]. Despite numerous studies, there have been minimal
therapeutic gains in patients presenting with metastatic disease
[Zhu et al., 2013]. Even though chemotherapy is an important
component of therapy, few changes to standardized care have been
implemented over recent decades. The deﬁcit in therapeutic gains for
OSA is due, in part, to the fact that little is known concerning the
tumorigenic process and cell of origin for OSA. Deﬁning the cells
that contribute to the development of OSAwill enhance the ability to
identify therapeutic targets.
Bone is a complex tissue composed of numerous cell types. The
mineralized portion of bone is primarily composed of osteoblasts,
which promote new bone growth, osteoclasts, which resorb old and
damaged bone, and osteocytes, which orchestrate the activities
of osteoblasts and osteoclasts. Osteocytes (OCy) are terminally
differentiated osteoblasts that become sequestered in mineralized
bone [Bonewald, 2011]. OCy are also the most abundant cell type in
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mineralized bone, comprising over 90% of cells [Bonewald, 2011].
OCy are responsible for maintaining bone homeostasis through
mechanosensation, the sensation of physical forces in the bone
environment, and mechanotransduction, the translation of physical
forces into biochemical signals that can be communicated to
surrounding cells. These processes are necessary to measure physical
forces and relate them to osteoblasts and osteoclasts, the effector
cells. OCy are long lived cells, in that a single OCy may have a
lifespan that measure decades [Franz-Odendaal et al., 2006]. The
ability of OCy to coordinate bone formation and lysis in the presence
or absence of mechanical stimuli makes them a unique cellular
component of bone.
OSA is typically described as producing mixed osteoblastic/
osteolytic regions within the tumor. This is unique as many cancers,
such as breast and prostatic carcinoma, metastasize to bone and
produce predominantly osteolytic or osteoblastic lesions, respec-
tively. Osteoblasts have been implicated as OSA progenitors
[Cao et al., 2005; Patane et al., 2006]. Due to the potential
for OSA to be derived from osteoblasts, OSA cell lines, such as
Saos2, are frequently utilized in many bone biology laboratories
for exploring osteoblast biology [Fogh et al., 1977; Rodan
et al., 1987; Czekanska et al., 2012]. However, due to their presence
in the bone and bone-remodeling ability, it is plausible that OCy
may also contribute to the development of OSA. Accordingly, the
goal of this study was to determine if OCy could serve as an OSA
precursor cell.
MATERIALS AND METHODS
CELL LINES
TheMLO-Y4murine osteocyte cell line wasmaintained as previously
described on collagen coated plates [Kato et al., 1997]. Plates were
collagen coated by incubating 0.02M acetic acid (Sigma Aldrich,
St. Louis, MO) and 0.15mg/ml rat tail type I collagen (BD
Biosciences, Bedford, MA) in PBS for 1 h at room temperature
before being washed with PBS. MLO-Y4 was maintained in a-MEM
(Cellgro, Henderson, VA) supplemented with 2.5% heat inactivated
fetal bovine serum (FBS; Gibco, Grand Island, NY), 2.5% heat
inactivated fetal calf serum (Hyclone, Logan, UT), and 1 penicillin/
streptomycin (Gibco). DLM8, K12, K7M2 (murine); Saos2 (human);
andAbrams, D17, Gracie, Moresco, OSCA40, Vogel (canine) cell lines
were maintained in high-glucose DMEM with 10% FBS and
1 penicillin/streptomycin. The HMPOS, HOS, OOS, and POS
(canine) cell lines were maintained in RPMI supplemented with 10%
FBS and 1 penicillin/streptomycin. The MG63 and SJSA1 (human)
cell lines were maintained in MEM with 10% FBS and 1 penicillin/
streptomycin. All cells were serially passaged by trypsinization and
maintained at 37 °C and 5% CO2 in a humidiﬁed atmosphere
(standard conditions).
ANIMALS
All animal studies were performed in an AALAC-approved facility,
with approval of the University Committee on Use and Care of
Animals (UCUCA) of the University of Michigan. Male severe
combined immunodeﬁciency disorder (SCID) mice 8–10 weeks of
age were used for all experiments, and were bred at the University of
Michigan. Five mice per group were used for all in vivo experiments.
IN VIVO TUMOR MODELING
Subcutaneous tumors were established by injecting 1 106 MLO-Y4
cells suspended in 1 Hank’s balanced salt solution (HBSS; Gibco)
into the right hind-ﬂank of the mouse. Tumors were measured twice
weekly using calipers, and tumor volume was calculated using the
formula V ¼ (S2 · L)/2, where L is the longest dimension measured
and S is the perpendicular measurement.
Orthotopic tumors were established as previously described
[Sottnik et al., 2010]. The proximal tibia was implanted with
1 106 MLO-Y4 cells while mice were under isoﬂurane anesthesia.
Weekly radiographs were obtained using a Faxitron MX-20
(Wheeling, IL) at 4 magniﬁcation. Orthotopic tumor growth was
assessed using a modiﬁed protocol previously described [Yin
et al., 1999]. Brieﬂy, radiographs were scanned at 600 dpi using a
UMAX Powerlook 1000 and Magic Scan V4.71 software (Techville,
Inc, Dallas, TX). It was determined that 600 dpi is equivalent to
55,800 pixels/cm2. Using Photoshop CS3 extended (Adobe Systems
Inc, USA) a region of interest was created encompassing the radio-
opaque area of the tibia between the growth plates. The number of
pixels within this areawas recorded. Pixel area (PA) was converted to
geometric area using the following formula:A¼ (PA 55,800) 4;
where 55,800¼ pixels/cm2 and 4 is the radiograph magniﬁcation.
IMMUNOHISTOCHEMISTRY
Following euthanasia, primary tumor, lung, liver, and spleen were
isolated from all animals, formalin ﬁxed, and parafﬁn embedded.
Organs were sectioned on three separate and distinct planes before
undergoing hematoxylin and eosin (H&E) staining. Each organ
section was then reviewed by a board-certiﬁed pathologist (R.M.) for
the presence of metastases.
Primary tumors from subcutaneous and orthotopically challenged
mice were stained for H&E, dentin matrix phosphoprotein 1 (DMP1;
Abcam, Cambridge, MA; 1:100), osteocalcin (OC;Millipore, Billerica,
MA; 1:500), vimentin (Bioss, Woburn, MA; 1:200), and pan-
cytokeratin (Bioss; 1:200). Antibody staining was accomplished
using an intelliPATH FLX (Biocare Medical; Concord, CA) automatic
staining system. Reveal decloaker (Biocare Medical) was used for
antibody retrieval followed by rodent block M (Biocare Medical) to
block non-speciﬁc binding. Primary antibodies were applied at
dilutions described above. Secondary anti-rabbit antibody conju-
gated to horse radish peroxidase (HRP) was utilized and followed by
staining with DAB followed by hematoxylin counterstaining
(Biocare Medical). Images were captured by an Olympus BX41
microscope with matching software.
REAL-TIME qPCR METHODS
For each cell line, near-conﬂuent cells were washed with 1 PBS,
RNA extracted with Trizol reagent (Invitrogen, Carlsbad, CA) and
puriﬁed using an RNeasy Mini-Kit (Qiagen, Valencia, CA) according
to manufacturer instructions. RNA concentrations were measured
using an ND-1000 Spectrophotometer (ThermoScientiﬁc, Wilming-
ton, DE). To maximize PCR sensitivity, 5mg of prepared RNA from
each cell line was reverse transcribed using the SuperScript III
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Reverse Transcriptase Kit (Invitrogen). Quantitative real time PCR
was performed in triplicate using SYBR Green qPCR MasterMix
(Qiagen) in a 10mL reaction volume on a Roche LightCycler
480 (Roche, Indianapolis, IN). Primers were purchased from
SABiosciences (Qiagen) or designed using NCBI RefSeq mRNA
sequences and NCBI Primer-BLAST software [Ye et al., 2012]. All
primers utilized, forward/reverse sequences, and amplicon length
can be found in Supplementary Tables I (Mouse), II (Human), and III
(Dog). Measurements from triplicate Ct values were averaged. Mean
Ct values of >30 cycles were considered negative (), 25–30 (þ),
20–24.99 (þþ), and <20 (þþþ). Beta-actin, GAPDH, and
b2-microglobulin were used as controls to ensure reaction activity.
All samples were positive (þþþ) for control gene expression.
WESTERN BLOT
Cells were grown to near conﬂuence before whole cell lysis using a
Triton X-100 based lysis buffer [1% Triton X-100, 20mM Tris-HCl,
137mMNaCl, 10% glycerol, 2mMEDTA, 1mMPMSF, 1mM sodium
orthovanadate, and protease inhibitor cocktail (Sigma-Aldrich,
St. Louis, MO)]. Protein quantiﬁcation was performed using a CBA
kit (Thermo-Scientiﬁc, Rockford, IL) with a SpectraMax M5 plate
reader (Molecular Devices, Sunnyvale, CA). Equal amounts of
proteinwere loaded on a 4–12%Bis-Tris gel (Invitrogen, Eugene, OR)
and electrophoresed in 1 MES/SDS running buffer (Invitrogen,
Carlsbad, CA). Bandswere transferred to a PVDFmembrane (Bio-Rad
Laboratories, Hercules, CA) and blocked using 5% instant milk
(Biorad) or 5% bovine serum albumin (BSA; Celliance, Kankakee, IL)
in tris-buffered saline with Tween 20 (TBST; 50mM Tris, 150mM
NaCl, and 0.05% Tween 20). Primary antibodies used were: rabbit
polyclonal anti-SV40 T-Antigen (Santa Cruz Biotechnology, Dallas,
TX), mouse monoclonal anti-p53 (Cell Signaling Technology,
Danvers, MA), syrian hamster monoclonal anti-podoplanin (Santa
Cruz Biotechnology), rabbit polyclonal anti-DMP-1 (Abcam), and
rabbit monoclonal anti-HSP90 (Cell Signaling). Primary antibodies
were diluted 1:1000 and incubated overnight at 4 °C. Donkey anti-
rabbit (Jackson Immunoresearch, West Grove, PA), donkey anti-
mouse (Jackson Immunoresearch), and goat anti-syrian hamster
(Santa Cruz Biotechnology) secondary antibodies conjugated to HRP
were used for detection. Detection was accomplished using ECL
reagent (Thermo-Scientiﬁc, Rockford, IL) and developed using
radiographic ﬁlm (Research Products International Corp., Mt.
Prospect, IL).
ONCOMINE STUDY
The ONCOMINE repository (www.oncomine.com) is a repository of
cDNA microarrays. Searching ONCOMINE for the term “osteosarco-
ma,”we identiﬁed 15 studies. Of the 15 studies identiﬁed, two did not
differentiate OSA speciﬁcally from sarcoma, 9 were composed
primarily of cell lines, and 1 only had a single OSA patient; thus these
studies were excluded from further analysis and the remaining three
were analyzed [Baird et al., 2005; Henderson et al., 2005; Kobayashi
et al., 2010]. The Kobayashi Sarcoma dataset was determined to have
the greatest number of patient samples (n¼ 27) for analysis and
differentiated OSA into subtypes [Kobayashi et al., 2010]. Baird
(n¼ 5; [Baird et al., 2005]) and Henderson (n¼ 11; [Henderson
et al., 2005]) data sets did not differentiate OSA subtypes but were
also analyzed. ONCOMINE was queried for genes associated with
OCy and OSA. Statistical analyses were performed using ONCOMINE
algorithms to adjust for multiple comparisons as previously
described [Rhodes et al., 2004; Sottnik et al., 2013].
STATISTICS
Statistical analysis was performed using Prism 5 (GraphPad
Software, La Jolla, CA). Doubling time for in vivo tumor growth
was determined by nonlinear regression of an exponential growth
curve for tumor growth. ONCOMINE data were analyzed as
previously described utilizing ONCOMINES algorithms [Rhodes
et al., 2004; Sottnik et al., 2013]. Supplemental analyses of the
Kobayashi dataset were performed using a two-tailed t-test
comparing osteoblastic OSA to all other OSA subtypes. For all
analyses, P-values of less than 0.05 were considered statistically
signiﬁcant.
RESULTS
ONCOMINE cDNA MICROARRAY ANALYSIS
The OCy speciﬁc gene DMP1 has been previously reported to be
expressed by OSA, suggesting that OCy may contribute to the
development of OSA [Kashima et al., 2013]. DMP1 expression is
characteristic of OCy [Bonewald, 2011]. Accordingly, the ONCO-
MINE microarray depository was queried for previous studies with
sufﬁcient data encompassing OSA patients. The Kobayashi sarcoma
dataset had the greatest number of patients for analysis (n¼ 27) and
was investigated for signiﬁcant expression differences in OCy
markers [Kobayashi et al., 2010]. DMP1 was expressed in 0/6 non-
osteoblastic OSA tumor samples, whereas 10/21 osteoblastic OSA
had DMP1 overexpression (Fig. 1; P< 0.001). Osteoblastic OSA is the
most common subtype of OSA, composing approximately 60% of all
cases [Mutsaers et al., 2013]. DMP1 was found to have a gene rank of
17, signifying that there were only 16 other genes with more
signiﬁcant P-values in the dataset (Fig. 1A; Supplemental Figure 1).
Signiﬁcant overexpression of the OCy-associated genes matrix
extracellular phosphoglycoprotein (MEPE), involved in integrin
association; and phosphate-regulating neutral endopeptidase
homolog x-linked (PHEX), involved in mineralization, were also
observed (Fig. 1; Supplemental Figure 1). Interestingly, alkaline
phosphatase (ALPL), which has been a controversial prognostic
factor in OSA biology [Bielack et al., 2009; Schmidt et al., 2013], was
not signiﬁcantly associated with osteoblastic OSA in this dataset.
When the dataset was analyzed for gene expression differences in
the above noted genes based on age, sex, primary tumor location,
metastasis at the time of diagnosis, or response to chemotherapy,
there was no signiﬁcant difference (P> 0.05) associated with
expression of OCy marker expression (data not shown).
We subsequently screened the Baird (n¼ 5; [Baird et al., 2005])
and Henderson (n¼ 11; [Henderson et al., 2005]) datasets for
expression of OCy markers in OSA patients (Supplementary
Figure 1). The Henderson dataset showed that DMP1 was
signiﬁcantly (P¼ 0.014) increased in OSA patients. Even though
the Baird dataset only had ﬁve OSA patients present, DMP1 was
increased, though not signiﬁcantly (P¼ 0.054). The Henderson
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dataset showed a signiﬁcant increased expression of MEPE
(P¼ 0.005) in OSA patients, but not PHEX. MEPE and PHEX were
not present in the Baird dataset and thus could not be analyzed. OSA
subtypes were not deﬁned in either the Baird or Henderson datasets.
Together, these data provide evidence of DMP1 overexpression in
clinical OSA.
EXPRESSION OF OSTEOCYTE MARKERS IN OSA CELL LINES
We next sought to determine if established OSA cell lines express
markers known to be associated with OCy. RNA was isolated from
murine, human, and canine OSA cell lines. cDNA was prepared and
qPCR performed for OCy-speciﬁc markers and other proteins
important in OSA biology (Supplemental Tables I–III). b-actin,
GAPDH, and b2-microglobulin were used as controls to ensure
reaction activity. As a control for OCy, we utilized the well-
characterized murine OCy cell line MLO-Y4. DMP1 and podoplanin
(Pdpn or e11/gp38) have been used to characterize OCy previously
[Franz-Odendaal et al., 2006; Zhang et al., 2006; Bonewald, 2011;
Woo et al., 2011; Kashima et al., 2013]. Murine OSA cell lines showed
low expression of the OCymarker Dmp1 (Table I). Pdpn (e11/gp38) is
the earliest expressed gene in OCys and high expression was
observed in all cell lines [Zhang et al., 2006]. The OCy related gene
Phex had robust expression in all cell lines; however, Mepe was not
observed in any of the cell lines. All cell lines expressed osteocalcin
(Bglap) to various degrees yet K12 and K7M2 did not express Alpl.
Osteocalcin expression has been shown to be associated with late
osteoblast and early OCy differentiation [Lee et al., 2007]. Sclerostin
(Sost) and receptor activator of nuclear factor kappa-B ligand
(RANKL) are the primary mediators by which OCymediate bone lysis
[Bonewald, 2011]. RANKL activity is opposed by osteoprotegerin
(OPG), a soluble inhibitor and decoy receptor for RANKL. MLO-Y4 is
a known low expresser of Sost [Yu et al., 2011] even though mature
OCy express Sost regularly [Wijenayaka et al., 2011]. Low expression
of Sost by MLO-Y4 has been attributed to the early differentiated
state of MLO-Y4 [Bonewald, 2011]. Sost was not expressed in MLO-
Y4, as previously described, or DLM8. However, Sost was expressed
in K12 and its more metastatic variant K7M2. Conversely, RANKL
was expressed to a greater degree by the Sost negative cell MLO-Y4
and DLM8, with lower expression in K12 and K7M2 cell lines. Bone
sialoprotein (integrin binding sialoprotein; Ibsp) is a component of
mineralized tissues and indicative of the differentiation of mature
osteoblasts into OCy. DLM8 had the greatest expression of Ibsp while
no other cell expressed Ibsp. Together, these data show the complex
expression proﬁle of OSA and the expression of various OCymarkers
by established murine OSA cell lines.
We investigated the expression of OCymarkers in the human OSA
cell lines Saos2, MG63, and SJSA1 (Table II). Saos2 has been
previously described asmore representative of osteoblastic OSA than
MG63 and SJSA1, which are described as more ﬁbroblastic, by ATCC
(the American Type Culture Collection) and independent inves-
tigators [Pautke et al., 2004; Mohseny et al., 2011]. Saos2 was the
only cell line to express DMP1. Since Saos2 is the only human cell
line with an osteoblastic phenotype, these data are similar to the
observations from the ONOCOMINE study. Saos2 expressed both
MEPE and PHEX, similar to the results obtained from the murine
OSA cell lines. However, MG63 and SJSA1 only expressed one of
Fig. 1. Human patients with osteoblastic OSA have increased expression of osteocyte-speciﬁc genes. The ONCOMINE database was searched for the term “osteosarcoma.”
The Kobayashi sarcoma dataset was identiﬁed as having sufﬁcient information for further analysis. OSA subtypes were analyzed for comparison of the OCy speciﬁc markers:
(A) dentin matrix protein-1 (DMP1), (B) matrix extracellular phosphoglycoprotein (MEPE), and (C) phosphate-regulating neutral endopeptidase homolog x-linked (PHEX).
(Heatmap of data present in Supplemental ﬁgure 1). Results are reported as log2 median-centered intensity as reported by ONCOMINE. *P < 0.05.
TABLE I. Expression of Osteocyte Markers from Murine OSA Cell
Lines
MLO-Y4 DLM8 K12 K7M2
alpl þþ þ þ  
bglap þ þ þ þ þ þ þ þ
ibsp  þ þ  
dmp1 þ þ þ þ
fgf23  þ þ þ
mepe    
opg þ þ þ þ þ þ þ
pdpn þ þ þ þ þ þ þ þ þ þ þ
phex þ þ þ þ þ þ
sost   þ þ
tnfsf11 þ þ þ þ  
b-actin þ þ þ þ þ þ þ þ þ þ þ þ
gapdh þ þ þ þ þ þ þ þ þ þ þ þ
RNA was isolated from murine OSA cell lines, reverse transcribed, and assayed
using qPCR. OSA marker expression was scored based on mean qPCR Ct values
as follows: >30; þ, 25–30; þþ, 20–25; þþþ, <20.
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these markers each. PDPN was expressed by MG63 and SJSA1.
Moderate expression of ALPL was present across all cell lines, but
only low expression of BGLAP was observed in Saos2. IBSP was
expressed in MG63 and SJSA1 but not in Saos2. The expression of
ALPL, BGLAP, and IBSP paint a complex picture concerning the
derivation and OSA subtype as previously described [Pautke
et al., 2004]. We observed that only Saos2 expressed RANKL, with
none of the cell lines expressing SOST, differing from the mouse cell
lines where cells predominantly expressed one or the other.
Interestingly, OPG was highly expressed in MG63 and to a lesser
degree in Saos2 and SJSA1.
Dogs have a relatively high incidence of OSA compared to
humans, and in many ways are uniquely suited for the study of OSA
due to high incidence of disease and similar pathology [Fan, 2010;
Schmidt et al., 2013]. Screening of numerous canine OSA cell lines
show similar trends to those observed in the murine and human OSA
cell lines; expression of Dmp1, Pdpn, and Bglap with mixed
expression of Alpl (Table III). Expression of Fgf23, Phex, and RANKL
was relatively low across the cell lines queried. Taken together, these
results suggest that OCy are an additional cell type for the
origination of OSA across species.
PROTEIN EXPRESSION OF OSTEOCYTE MARKERS
To conﬁrm that the qPCR results for the OCy-speciﬁc markers
reﬂected actual protein production, whole cell lysates were created
from near conﬂuent murine OSA cell lines. Since MLO-Y4 was
created by expressing SV40-transduced large T antigen under a rat
osteocalcin promoter, we investigated SV40 large T-antigen
expression and observed that only MLO-Y4 expresses SV40 large
T Antigen (Fig. 2) as previously described [Kato et al., 1997]. MLO-Y4
had an overexpression of p53, likely due to SV40 expression and
transformation. However, p53 is a known driver of OSA, and all
murine cell lines were found to express p53 (Fig. 2) [Berman
et al., 2008].
Next we sought to validate the expression of OCy markers by
protein expression as we previously demonstrated by RNA
expression. Indeed, all cell lines expressed PDPN to varying degrees
conﬁrming the qPCR results (Fig. 2). DMP1 was expressed in all cell
lines investigated, though with greater variability than observed by
qPCR (Fig. 2). Protein expression of DMP1 and PDPN is characteristic
of OCy. HSP90 was used as a loading control. These data show that
murine OSA cell lines express markers characteristic of the OCy
phenotype.
CHARACTERIZATION OF THE TUMOROGENICITY OF MLO-Y4 CELLS
Transduction of cells with SV-40 large T antigen has been used to
create multiple models of various tumor types, including OSA,
breast, and prostate cancer, [Atkin et al., 2009; Pipas, 2009]. Thus
we determined if large T antigen conferred an OSA phenotype on
MLO-Y4 cells. Initially, to determine if MLO-Y4 cells are
tumorigenic, 1 106 cells were implanted subcutaneously (SQ) in
SCID mice. MLO-Y4 cells produced SQ tumors with a doubling time
of 3.2 days (r2¼ 0.523; Fig. 3A). We subsequently injected mice
intratibially (IT) with the MLO-Y4 cells to recapitulate the orthotopic
environment of OSA. Orthotopic tumors developed and induced
radiographically-deﬁned mixed osteoblastic/osteolytic lesions
similar to that observed in OSA patients (Fig. 3B). Tumor burden
was semi-quantiﬁed by measuring the radiographic area of the
tumor from weekly radiographs as previously described for intra-
osseous tumors [Yin et al., 1999]. Orthotopic tumors were observed
to have a doubling time of 36.3 days (r2¼ 0.605; Fig. 3C). Mice were
euthanized 6 weeks after challenge due to primary tumor size. Gross
metastases were not observed.
TABLE II. Expression of Osteocyte Markers from Human OSA Cell
Lines
MG63 Saos2 SJSA1
ALPL þ þ þ þ þ
BGLAP  þ 
IBSP þ  þ
DMP1  þ 
FGF23   
MEPE  þ 
OPG þ þ þ þ þ þ
PDPN þ þ  þ þ
PHEX þ þ 
SOST   
TNFSF11  þ 
b-ACTIN þ þ þ þ þ þ þ þ þ
GAPDH þ þ þ þ þ þ þ þ þ
RNA was isolated from human OSA cell lines, reverse transcribed, and assayed
using qPCR. OSA marker expression was scored based on mean qPCR Ct values as
follows: >30; þ, 25–30; þþ, 20–25; þþþ, <20.
TABLE III. Expression of Osteocyte Markers from Canine OSA Cell Lines
Abrams D17 Gracie HMPOS HOS Moresco OOS OSCA40 POS Vogel
Alpl    þ þ     þ þ 
Bglap þ þ þ þ þ þ þ þ þ þ
Dmp1 þ þ þ  þ þ þ þ  þ
Fgf23  þ      þ  
Pdpn þ þ þ þ þ þ þ þ þ  þ þ þ þ þ
Phex þ    þ þ  þ  
Tnfsf11      þ þ  þ þ
b-actin þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
b2-microglobulin þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
RNA was isolated from canine OSA cell lines, reverse transcribed, and assayed using qPCR. OSA marker expression was scored based on mean qPCR Ct values as follows:
>30; þ, 25–30; þþ, 20–25; þþþ, <20.
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HISTOLOGIC ANALYSIS OF MLO-Y4 TUMORS
To examine the histologic features of the resulting MLO-Y4 tumors,
SQ and orthotopic tumors were formalin ﬁxed and parafﬁn
embedded. Similar ﬁndings for SQ and orthotopic tumors were
observed. Multiple organs from mice with orthotopic tumors were
evaluated by conventional H&E histology to investigate metastatic
tumor development; however no metastases were observed in the
lung, liver, or spleen. H&E stained sections from primary tumors
demonstrated a predominantly high grade spindle cell malignant
neoplasm with cells demonstrating coarse chromatin and increased
mitotic activity. However, no obvious osteoid production was
identiﬁed in these tumors.
To further histologically characterize the tumor tissue of origin,
immunohistochemistry for vimentin and pan-cytokeratin was
performed. Vimentin is a marker of mesenchymal cells; whereas,
pan-cytokeratin is attributed to epithelial-derived cells. Vimentin
expression has previously been associated with OSA [Barger
et al., 2005]. In this study, normal bone marrow and osteoblasts
were found to positively express vimentin. Tumors resulting from
MLO-Y4 injection were found to have strong cytoplasmic vimentin
expression suggestive of their mesenchymal differentiation (Fig. 4).
However, pan-cytokeratin expression in tumor was negative (data
not shown). These observations identify that MLO-Y4 tumors have a
mesenchymal phenotype consistent with what is expected for OSA.
To characterize the bone cell of origin for the MLO-Y4 tumors
immunohistochemistry for osteocalcin and DMP1 was performed.
Osteocalcin staining was observed in cells of the osteoblast lineage
of normal bone (Fig. 4). Even though osteocalcin has been observed
to be highly expressed in MLO-Y4 cells in culture [Qin et al., 2007],
we observed onlymoderate staining in tumor sections (Fig. 4). DMP1
was found to characteristically stain matrix surrounding OCys
localized to the lacunar canalicular system of normal bone as
previously described (Fig. 4) [Kashima et al., 2013]. DMP1 was found
to be strongly expressed in the cytosol of tumor cells. DMP1 is known
to be secreted and act as a positive factor in mineralization
[Qin et al., 2007]. Thus, these data demonstrate that MLO-Y4 tumors
express (1) a mesenchymal phenotype (2) a late osteoblast/early OCy
marker (osteocalcin), and (3) the OCy-speciﬁc marker DMP1. Taken
together, these data indicate that OCy can serve as an OSA
progenitor.
Fig. 3. MLO-Y4 are tumorigenic in SCID mice. MLO-Y4 were injected
subcutaneously (SQ) and orthotopically (intratibial; IT). A) Caliper
measurements of SQ tumors were used to determine tumor volume as
measured twice weekly. B) Weekly radiographs of IT tumors of a representative
mouse are shown. C) Measurement of cross-sectional tumor area measured
from radiographs of IT tumors.
Fig. 2. Protein expression of osteocyte speciﬁc genes from murine OSA cell
lines. Whole cell lysates from murine OSA cell lines and MLO-Y4 OCys were
examined by Western blot. Since MLO-Y4 is SV40 large T-antigen transduced,
we probed for SV40 large T antigen and p53. To determine the expression of
OCy-speciﬁc markers, DMP1 and PDPN were examined. HSP90 was used as a
loading control.
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Fig. 4. Immunohistochemistry of osteocyte speciﬁc markers in MLO-Y4 tumors. Mice were injected with 1 106 MLO-Y4 cells orthotopically, in the tibia. After 6 weeks, mice
were euthanized and tumor was formalin ﬁxed and parafﬁn embedded. Immunohistochemical analysis of MLO-Y4 tumors and contralateral normal limbs was performed.
A) Tumor was histologically assessed by H&E staining. B) Further characterization of the tumor was achieved by staining for vimentin (mesenchymal phenotype), osteocalcin
(late osteoblast/early OCy), and DMP1 (OCy origin).
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DISCUSSION
In this study, we provide both expression and functional evidence
that OCys can serve as a cell of origin of OSA. Additionally we have
shown that a transformed OCy cell line, MLO-Y4, is tumorigenic in
mice. The transition from osteoblast to OCy is a complex process with
ill-deﬁned endpoints [Woo et al., 2011]. For example, the expression
of ALP and OC are common to both cell types, with ALP declining
during the transition and OC increasing. It is during this time that
markers characteristic of osteocytes, such as DMP1, PDPN, and
MEPE begin to be expressed. Expression of PDPN and DMP1
have been described as the earliest markers associated with OCy
[Franz-Odendaal et al., 2006; Zhang et al., 2006; Bonewald, 2011;
Woo et al., 2011; Kashima et al., 2013]. OCy further differentiate
leading to expression of markers such as RANKL, FGF23, and SOST
[Franz-Odendaal et al., 2006; Bonewald, 2011]. The OCy cell line
MLO-Y4 expresses DMP1, PDPN, Phex, and RANKL, consistent with
previous reports describing these cells as OCy [Franz-Odendaal
et al., 2006; Zhang et al., 2006; Bonewald, 2011; Woo et al., 2011;
Kashima et al., 2013] Many established OSA cell lines investigated
also express these markers. Data presented herein support OCy as a
progenitor cell of OSA in addition to osteoblasts.
It is likely that transformation of MLO-Y4 occurred due to the
introduction of SV40 large T-antigen during development of the cell
line. SV40 large T antigen can transform cells by inactivating p53
and retinoblastoma (pRb); both molecules are critical in promoting
apoptosis [Lane and Crawford, 1979; Levine and Oren, 2009]. SV40-
based transformation has not only been used as a mechanism to
promote murine models of OSA [Knowles et al., 1990; Marton
et al., 2000; Jones, 2011], but SV40 DNA has also been observed in
human patients with OSA [Lednicky et al., 1997]. Mutations and
inactivations of p53 and pRb are known drivers of OSA [Berman
et al., 2008; Walkley et al., 2008]. This does not diminish the
usefulness ofMLO-Y4 as a tool for the study of OCy biology, but does
provide an additional caveat for its use. It is not uncommon for
tumor cell lines to provide the basis for understanding physiologic
processes. For example, the human OSA cell line Saos2 is widely
utilized for the study osteoblast biology withMG63 to a lesser degree
[Czekanska et al., 2012].
A majority of patients diagnosed with OSA have metastases at the
time of diagnosis, with the majority being lung metastases. We
investigated if MLO-Y4 is capable of producing spontaneous
metastases from an orthotopic location. However, no metastases
were observed in the lung, liver, or spleen of these mice. Even though
metastases signiﬁcantly increase the usefulness of a model, many
OSA cell lines have required selection of metastatic variants to
increase metastatic ability of weakly metastatic cell lines [Asai
et al., 1998; Barroga et al., 1999; Khanna et al., 2000; Kimura
et al., 2002; Su et al., 2009]. Furthermore, it is possible in the murine
model, that the primary tumor grows rapidly, not allowing time for
metastases to manifest as the mouse must be euthanized due to the
large primary tumor. It may also be possible to develop metastatic
variants of MLO-Y4 by selecting lung metastases after intravenous
challenge similarly to the murine OSA cell lines DLM8 and K7M2
[Asai et al., 1998; Khanna et al., 2000]. We observed expression of
PDPN, an early OCy marker, in a majority of the OSA cell lines
studied conﬁrming previous reports that PDPN is aberrantly
expressed in OSA [Kunita et al., 2011]. PDPN is known to also
play a role in platelet aggregation and has been proposed as a
plausible target to inhibit OSA metastases [Kunita et al., 2011].
To investigate if the OCy markers DMP1, MEPE, and PHEX were
associated with metastasis, we performed a post-hoc analysis of the
Kobayashi sarcoma dataset from ONCOMINE [Kobayashi
et al., 2010]. No signiﬁcant association was present. Even though
the Kobayashi dataset was the largest OSA dataset present, it is still
relatively small with only 27 patients analyzed. A lack of statistical
power may have led to the non-signiﬁcant result. It is also plausible
that the OCy factors DMP1, MEPE, and PHEX are not prognostic or
associated with the development of metastases. Expression of these
proteins by OSA tumors and cell lines suggests OCy as an ancestral
cell to the resulting tumor. Investigation of human cell lines also
described osteoblastic OSA (Saos2) as expressing DMP1; whereas,
those described as ﬁbroblastic OSA (MG63 and SJSA1) did not
express DMP1. Results obtained from the Baird and Henderson
datasets provide further evidence of DMP1 overexpression in OSA
[Baird et al., 2005; Henderson et al., 2005]. These data correlate with
the patient data suggesting DMP1 is expressed predominantly by
osteoblastic OSA and are important in describing the etiology
of OSA. DMP1, MEPE, and PHEX belong to the SIBLING
(small integrin-binding ligand N-linked glycoproteins) family of
proteins. The SIBLING family members osteopontin (OP) and IBSP
have previously associated with a metastatic phenotype [Bellahcene
et al., 2008]. Association of SIBLING family members in epithelial
derived tumors and osteotropic metastatic disease has also been
observed [Bellahcene et al., 2008]. Therefore, further investigation is
necessary to determine if DMP1, MEPE, and PHEX play a role in OSA
metastasis or may be of use as prognostic factors.
OSA typically forms mixed osteoblastic/osteolytic lesions. We
observed these changes on radiographs but did not observe osteoid
production in subcutaneous or orthotopic tumors. It is unclear why
these differences persist, but it is plausible that these are primarily
lytic lesions masked by the normal bone architecture. OCys do not
secrete components of extracellular matrix, but do secrete molecules
to mineralize ECM. It is possible that OCy are capable of mineralizing
ECM, but other cells must be present to produce the more immature
bone matrix. There is little evidence, most of it contradictory,
concerning the ability of OCys to create or resorb bone on their own
[Wysolmerski, 2013]. OCys are unique bone cells whose primary role
is the sensation of physical forces in the bonemicroenvironment and
conversion of those signals into biochemical signals. OCys
coordinate osteoblastic and osteolytic responses. Expression of
OPG, RANKL, and SOST are the primary mediators used to activate
osteoblasts or osteoclasts, respectively. We observed mixed expres-
sion of RANKL, OPG, and SOST from OSA cell lines, but observed
cells expressing either RANKL or SOST. All murine OSA cell lines
expressed OPG. Therefore, the potential for antagonistic responses
from OCy are plausible dependent on the microenvironment.
Nevertheless, it is plausible that the mixed lesions characteristic of
OSA are due to the underlying OCy nature of the cells driving these
tumors. OCys provide a mechanism by which local alterations in the
microenvironment lead to osteoblastic or osteolytic regions. Since
OCy coordinate osteoblastic/osteolytic responses physiologically, it
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is plausible that a tumor composed of, or derived from, OCywould be
capable of employing both arms of bone maintenance resulting in
characteristically mixed lesions.
The observations made herein incite new questions concerning
the etiology of OSA. The development of tumor from what are
believed to be terminally differentiated cells is important as these
cells should not be proliferative. Further investigation concerning
the importance of OCy speciﬁc factors to OSA progression and
metastasis must also be investigated. Recently, Kashima et al.
published data showing that DMP1 is speciﬁcally expressed by OSA
[Kashima et al., 2013]. Their immunohistochemical investigation of a
large sample size of primary bone tumors supports our conclusion
that osteoblastic OSA speciﬁcally expresses DMP1 and that OCymay
serve as a progenitor cell for OSA. These observations suggest that
OCy may act as a cell of origin for OSA in addition to osteoblast.
Analysis of the Kobayashi dataset depicted 10 of 21 osteoblastic OSA
patients expressing DMP1 [Kobayashi et al., 2010]. Targeted
inactivation of p53 and pRb has previously been shown to promote
OSA [Berman et al., 2008; Walkley et al., 2008]. Therefore,
it is plausible that OCy are a novel cell of origin for OSA in addition
to osteoblasts. Further investigation is necessary to determine how
the cell of origin alters metastasis and potentially long-term
survival.
The observation that OSA develops from OCy may provide novel
methods for clinical intervention. By better understanding OCy, and
how they react to their environment, we may be able to develop
novel methods of inhibiting OSA growth and metastasis. OCy
biology has not been as elucidated in the same detail as osteoblasts
and osteoclasts even though OCy comprise a much larger percentage
of bone. Ongoing studies to explore the functional relationship of
OCy with other cells in the bone microenvironment may lead to
novel pathways and targets for OSA. Understanding that OCys may
give rise to OSA is of importance for understanding the underlying
tumor biology of OSA, and discovering newmethodologies than can
be exploited to inhibit this aggressive bone disease.
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